Exelixis | EXEL - Market Capitalization



Exelixis reported $10.67B in Market Capitalization this September of 2025, considering the latest stock price and the number of outstanding shares.


Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.61B 840M Jun/2025
Agios Pharmaceuticals USD 1.93B 234M Jun/2025
Amgen USD 150.13B 17.37B Jun/2025
AstraZeneca GBP 215.51B 41B Jun/2025
Bayer EUR 25.09B 3.38B Jun/2025
BioMarin Pharmaceutical USD 10.54B 3.01B Jun/2025
Bristol-Myers Squibb USD 94.2B 29.9B Jun/2025
Cytokinetics USD 3.95B 846M Jun/2025
Eli Lilly USD 738.79B 2.87B Jun/2025
Genmab DKK 80.88B 7.82B Jun/2025
Glaxosmithkline USD 82.21B 2.63B Sep/2025
Incyte USD 13.18B 1.46B Jun/2025
Ionis Pharmaceuticals USD 6.29B 1.49B Jun/2025
MacroGenics USD 111M 34M Sep/2025
Merck USD 198.77B 27.1B Jun/2025
Moderna USD 10.67B 290M Jun/2025
Neurocrine Biosciences USD 12.44B 1.5B Jun/2025
Novartis CHF 256.18B 64.49B Jun/2025
Pfizer USD 137.53B 6.19B Jun/2025
Sanofi USD 125.19B 7.59B Sep/2025
Takeda JPY 7.04T 19.15B Jun/2025
Ultragenyx Pharmaceutical USD 3.44B 38M Jun/2025
Xencor USD 559M 191M Jun/2025